Computational Biology Market by Services, Application, End-Use

List of Tables

[193 Pages Report] The Computational Biology Market size was estimated at USD 6.25 billion in 2023 and expected to reach USD 7.42 billion in 2024, at a CAGR 18.91% to reach USD 21.01 billion by 2030.

Computational biology is an interdisciplinary domain that applies techniques from computer science, applied mathematics, statistics, and bioinformatics to solve complex problems in biology, understand biological data, and model biological systems. It encompasses the development and application of theoretical methods and data-analytical, computational simulation techniques, and mathematical modeling to the study of biological, behavioral, and social systems. The primary aim of this technology is to generate insights into the principles and dynamics of biological systems, as well as to predict their behaviors and interactions. Computational biology is closely related to the field of bioinformatics but tends to focus more on the development of theoretical approaches and computational models. The computational biology market is driven by the increasing need for drug discovery and personalized medicine, advancements in the field of bioinformatics, and the rise in the volume of complex biological data. Government and private funding for research and development in genomics and proteomics also support the market expansion. Despite growth prospects, the need for specialized computational infrastructure, high costs associated with computational tools, and a shortage of skilled professionals to analyze biological data hinder the scope of computational biology. Moreover, concerns regarding data security and privacy and the complexity of regulatory compliances for healthcare-related data create hurdles in market proliferation. However, an integration of artificial intelligence and machine learning algorithms is further presenting lucrative opportunities for market growth by enhancing predictive modeling and data analysis capabilities. Moreover, the rising focus on biomarker discovery and its role in precision medicine opens up new opportunities for the market's expansion.

KEY MARKET STATISTICS
Base Year [2023]	USD 6.25 billion
Estimated Year [2024]	USD 7.42 billion
Forecast Year [2030]	USD 21.01 billion
CAGR (%)	18.91%

Services: Benefits of in-house computational biology capabilities to handle sensitive data or proprietary research

In the dynamic field of computational biology, contract based services stand out as a flexible solution for organizations seeking specialized expertise without the overhead of full-time employment. These services, offered by external providers or individual consultants, are tailored to meet the specific project demands and timelines, making them an invaluable resource for companies that require advanced analytical skills, state-of-the-art algorithm development, or custom bioinformatics software solutions on a temporary or per-project basis. In contrast, in-house computational biology services are integrated within an organization's permanent operational structure. This approach allows for a consistent and long-term investment in computational biology expertise, fostering a deep understanding of the company's specific research areas and methodologies. In-house teams are intimately familiar with the data, objectives, and processes of their organization, enabling them to align their output closely with the strategic goals of the business. They provide a stable and continually evolving resource capable of adapting to the company's changing needs over time.

Application: Significant applications of computational biology to streamline the drug development pipeline

Cellular biological simulation involves the use of computational models to simulate the behaviors and interactions of biological cells. These simulations help to understand and predict cellular functions, biological behaviors, and responses to various stimuli, which is critical for both basic research and applied biomedical applications. The technology is especially relevant for investigating complex biochemical pathways and in silico experimentation, which can be cost-prohibitive or technically challenging to perform in vitro or in vivo. Clinical trials are experimental research studies conducted to determine the efficacy of new drugs, medical devices, or treatment protocols on human subjects. Computational biology plays a pivotal role in the design and analysis of clinical trials, improving the efficiency of trial designs, patient stratification, and data analysis. Drug discovery & disease modeling are crucial applications of computational biology where computer-aided design (CAD) for drug compounds and modeling of disease pathways accelerate the discovery of new therapeutics. These methods enable the exploration of vast chemical spaces and the modeling of complex diseases, respectively, to identify potential targets and molecules for new drugs. Human body simulation software encompasses a broad set of computational tools designed to model anatomical and physiological aspects of the human body. These simulations are employed for a variety of applications, including medical device design, surgical planning, and educational purposes. Preclinical drug development is the phase of research that precedes clinical trials in the drug development process. It involves the use of in silico models and simulation tools to predict the pharmacokinetics, pharmacodynamics, and toxicity of candidate drugs.

End-Use: Growing adoption of computational biology in commercial entities to tackle applied research challenges

In academic settings, computational biology tools are primarily used for research and educational purposes. The emphasis is on accessibility to cutting-edge technology, ease of use for students and researchers, and cost-effectiveness. Academic institutions often require extensive databases and computational power for diverse research ranging from evolutionary biology to systems biology. Commercial entities, including pharmaceutical and biotech companies, prioritize the application of computational biology for drug discovery and development, personalized medicine, and agrigenomics. These sectors seek robust, scalable solutions with a strong emphasis on data security and intellectual property protection.

Regional Insights

The computational biology market in the Americas, particularly in North America, is exhibiting robust growth. The presence of established pharmaceutical companies, sophisticated healthcare infrastructure, and rigorous research and development activities are propelling the region's market expansion. Large-scale investments in genomics and proteomics are further spurring demand for computational biology solutions. The United States remains at the forefront, backed by supportive government policies, substantial academic-industry collaborations, and an increase in bioinformatics-related courses that supply skilled professionals to the field. The EMEA region has been experiencing a significant surge in the computational biology market owing to increased funding by private and public entities, particularly in Europe. Efficient regulatory frameworks for drug development and a tradition of excellence in scientific research are driving the market's progress in this region. Germany, the UK, and France are major contributors with their strong focus on biotechnology and computational sciences. The Middle East is steadily catching up, largely due to strategic government investments in the biotech sector, while Africa is in the early stages of development. Asia-Pacific is emerging as a dynamic growth hub for the computational biology market. Rapid economic development, increasing healthcare expenditure, and a burgeoning biotechnology industry characterize the market landscape. Countries in the region are providing lucrative opportunities for market players owing to governmental backing, a focus on education and research in the life sciences, and a rising emphasis on personalized medicine. Cross-border collaborations and the inflow of foreign investments are further defining this market, positioning APAC as a competitive and high-potential region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Computational Biology Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Computational Biology Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Computational Biology Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BGI Group, Biomax Informatics AG, Chemical Computing Group Inc., Compugen Ltd., Dassault Systemes SE, DNAnexus, Inc., DNASTAR, Inc., Eurofins Scientific SE, Genedata AG, Illumina, Inc., Insilico Medicine, Instem Group, Nimbus Discovery Llc, Ocean Genomics, PerkinElmer, Inc., Pluto Bioinformatics, ProFound Therapeutics, QIAGEN N.V., Rosa & Co. Llc, Schrodinger, Inc., Simulation Plus Inc., SOPHiA GENETICS, Thermo Fisher Scientific Inc., Waters Corporation, and WuXi NextCODE.

Market Segmentation & Coverage

This research report categorizes the Computational Biology Market to forecast the revenues and analyze trends in each of the following sub-markets:

Services
- Contract
- In-house

Application
- Cellular Biological Simulation
- Clinical Trials
- Drug Discovery & Disease Modelling
- Human Body Simulation Software
- Preclinical Drug Development

End-Use
- Academics
- Commercial

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Computational Biology Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Computational Biology Market?

3. What are the technology trends and regulatory frameworks in the Computational Biology Market?

4. What is the market share of the leading vendors in the Computational Biology Market?

5. Which modes and strategic moves are suitable for entering the Computational Biology Market?

Product Code: MRR-433AB1DC289D

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising Need for Personalized Medicine
  - 5.1.1.2. Growing Bioinformatics Research and Increasing Number of Clinical Studies
  - 5.1.1.3. Adoption of Computational Biology in Oncology Therapeutics
- 5.1.2. Restraints
  - 5.1.2.1. Dearth of Skilled Professionals to Operate Computational Tools
- 5.1.3. Opportunities
  - 5.1.3.1. Accelerating Use of Bioinformatics and Multiscale Biological Modeling in Cell Modeling
  - 5.1.3.2. Increased Funding in Bioinformatics Coupled with Advancements in the Field of Computational Biology
- 5.1.4. Challenges
  - 5.1.4.1. Insufficiency of Interoperability and Multiplatform Capabilities and Lack of Well-Defined Standards
5.2. Market Segmentation Analysis
- 5.2.1. Services: Benefits of in-house computational biology capabilities to handle sensitive data or proprietary research
- 5.2.2. Application: Significant applications of computational biology to streamline the drug development pipeline
- 5.2.3. End-Use: Growing adoption of computational biology in commercial entities to tackle applied research challenges
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Computational Biology Market, by Services

6.1. Introduction
6.2. Contract
6.3. In-house

7. Computational Biology Market, by Application

7.1. Introduction
7.2. Cellular Biological Simulation
7.3. Clinical Trials
7.4. Drug Discovery & Disease Modelling
7.5. Human Body Simulation Software
7.6. Preclinical Drug Development

8. Computational Biology Market, by End-Use

8.1. Introduction
8.2. Academics
8.3. Commercial

9. Americas Computational Biology Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Computational Biology Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Computational Biology Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. New Funds Available for Early Career Canadian Researchers Building Careers in Bioinformatics, Computational Biology, or Health Data Sciences
- 12.3.2. Pluto Announces USD 3.7M Seed Round, Led by Silverton Partners
- 12.3.3. Accenture Invests in Ocean Genomics to Accelerate AI-driven Drug Discovery and the Development of Personalized Medicines

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio